C100: A Game-Changer in Cancer Immunotherapy?

Описание: Here are the Assay Genie antibodies used in this paper:

https://www.assaygenie.com/anti-mouse...
https://www.assaygenie.com/mouse-igg2...
https://www.assaygenie.com/anti-mouse...

In this video, we explore a groundbreaking study from Cell Reports Medicine titled "Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8⁺ T cell-dependent anti-tumor immunity."

Researchers from Trinity College Dublin and collaborators have developed C100, a highly deacetylated chitin-derived polymer that activates the STING pathway in tumors—without triggering harmful inflammation. Unlike traditional STING agonists, C100 selectively activates type I interferon responses and bypasses NF-κB, making it a promising tool for in situ cancer vaccination and checkpoint blockade synergy.

🧬 We’ll break down:

Why current STING agonists often fail

How C100 works at the cellular level

Its synergy with anti-PD-1 therapy

Why CD8⁺ T cells are crucial to its success

What this means for future cancer immunotherapy

📄 Full paper: https://doi.org/10.1016/j.xcrm.2024.1...

#CancerImmunotherapy #STING #C100 #Immunology #TrinityCollegeDublin #CheckpointBlockade #ScienceExplained #CellReportsMedicine